Last reviewed · How we verify

NCT01242098: Fos/Ser_switch

Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management

Completed Last updated 7 June 2012
What this trial tests

trial testing Fixed dose combination salmeterol / fluticasone in Asthma in 137 participants. Completed in 1 December 2011.

Timeline
1 January 2008
Primary endpoint
1 December 2011
1 December 2011

Quick facts

Lead sponsorResearch in Real-Life Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment137
Start date1 January 2008
Primary completion1 December 2011
Estimated completion1 December 2011
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Research in Real-Life Ltd — full company profile →

Who can join

Adults 18 to 80, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01242098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing